Dengrong Jiang1,2, Zixuan Lin1,2, Peiying Liu1, Sandeepa Sur1, Cuimei Xu1, Kaisha Hazel1, George Pottanat1, Jacqueline Darrow3, Jay J. Pillai1,4, Sevil Yasar5, Paul Rosenberg6, Abhay Moghekar3, Marilyn Albert3, and Hanzhang Lu1,2,7
1The Russell H. Morgan Department of Radiology & Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, United States, 2Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, United States, 3Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, United States, 4Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD, United States, 5Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States, 6Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, United States, 7F.M. Kirby Research Center for Functional Brain Imaging, Kennedy Krieger Research Institute, Baltimore, MD, United States
Synopsis
Alzheimer’s disease, vascular cognitive
impairment and their concurrence represent the most common types of cognitive
dysfunction. There exists a considerable overlap in their clinical symptoms and
neuroimaging features, and we still lack effective tools for their differential
diagnosis. This work demonstrated that cerebral oxygen-extraction-fraction
(OEF) was differentially affected by Alzheimer’s (decrease OEF) and vascular
(increase OEF) pathology. In individuals with low vascular risks, lower OEF was
associated with worse cognitive performance and greater amyloid burden. In
impaired patients, higher OEF was associated with great vascular risk factors.
These findings suggest OEF can be useful in etiology-based diagnosis of
cognitive impairment.
INTRODUCTION
Alzheimer’s disease (AD) and vascular cognitive
impairment (VCI), as well as their concurrence, represent the most common types
of cognitive dysfunction.1 Treatment strategies for the
two types can be very different. However, there exists a considerable overlap
in clinical symptoms and neuroimaging features between them,2
and we still lack effective tools for their differential diagnosis. Cerebral
oxygen-extraction-fraction (OEF) reflects a delicate balance between vascular
(e.g. blood supply) and neural (e.g. oxygen consumption) function.3,4 We
therefore hypothesize that, when the brain is characterized by
neurodegeneration with relatively intact vascular function (i.e. AD), OEF will
be diminished due to reduced oxygen consumption. On the other hand, when the
brain mainly suffers from vascular dysfunction (i.e. VCI), OEF will be elevated
due to decreased blood flow. In this work, we used a non-invasive and rapid MRI
technique5,6 to measure OEF, and examined its relationship
to Alzheimer’s pathology and vascular risk factors in a group of cognitively
impaired patients.METHODS
Participants
Sixty-five elderly subjects were included.
Each subject received a standard consensus diagnosis of being cognitively
normal, mild-cognitive-impairment (MCI), or dementia.7 All subjects underwent
neuropsychological tests covering four cognitive domains: verbal episodic
memory, executive function, processing speed, and language. Z-scores of each
domain were averaged to yield an overall composite cognitive score.
Based on medical histories, a
vascular-risk-score (VRS) was created by summing up five elements8: hypertension (1=recent,
0=remote/absent), hypercholesterolemia (1=recent, 0=remote/absent), diabetes
(1=recent, 0=remote/absent), smoking (1 if ≥100 cigarettes-smoked, 0 otherwise)
and body-mass-index (1 if >30, 0 otherwise).
In a subset of 43 subjects, cerebrospinal-fluid
(CSF) samples were collected through lumbar puncture. Concentrations (in
picograms/ml) of CSF β-amyloid-42 (Aβ42), β-amyloid-40 (Aβ40), total tau, and
phosphorylated tau (p-tau) were measured.
MRI Experiment
Global OEF of each subject was
measured using T2-relaxation-under-spin-tagging (TRUST)5,6 MRI. Our previous works have demonstrated
that TRUST provides accurate OEF quantification6 and has excellent inter-vendor
scalability.9 TRUST used the following parameters:
TR/TE/TI=3000/3.6/1020ms, scan time=1.2min. During the TRUST scan, end-tidal CO2
(EtCO2) of each subject was measured.
Data Processing
The processing of TRUST OEF data followed
literature.5,6 We previously showed that normal OEF
variations are largely (~50%) attributed to the subjects’ EtCO2
levels.10 Therefore, to reduce physiological variations,
OEF was corrected for EtCO2 using:
$$ OEF=OEF_{raw}-α(EtCO_2 - \overline{EtCO_2})$$ (1)
where $$$OEF_{raw}$$$ is
the OEF before correction, $$$\overline{EtCO_2}$$$
is
the averaged EtCO2 across subjects. α was found to be -0.87±0.16%/mmHg.
Statistical Analysis
Multi-linear
regression analyses were conducted in which OEF was the dependent variable
while VRS and diagnosis (0=normal, 1=MCI, 2=dementia) were independent
variables. A Diagnosis×VRS interaction term was also tested. If the interaction
effect was significant, we then divided the subjects into subgroups: a low-VRS
(≤2) subgroup and a high-VRS (>2) subgroup; or a normal subgroup and an
impaired (MCI/dementia) subgroup, and examined their relationships to OEF. The
associations of OEF with cognition and CSF amyloid or tau pathology were also
examined. Age and sex were covariates in all analyses.RESULTS AND DISCUSSION
Table 1 lists the subjects’
characteristics. Figure 1 shows representative TRUST OEF data. Multi-linear
regression analysis (Table 2, Model 1) revealed that OEF was negatively associated
with diagnosis (P=0.02) but positively associated with VRS (P=0.02).
Furthermore, a significant Diagnosis×VRS
interaction effect was observed (P=0.04, Table 2, Model 2). Therefore,
we divided the subjects into subgroups and conducted further analyses. We first
divided the subjects by VRS. In the low-VRS subgroup (N=44), OEF was inversely
associated with diagnosis (P=0.01, Figure 2a). Since the low-VRS
impaired individuals are likely attributed primarily to AD, this observation
supports our hypothesis that AD results in diminished OEF. On the other hand, in the high-VRS subgroup (N=21), OEF
was not associated with diagnosis (P=0.95, Figure 2b).
Next, we separated the subjects by
diagnosis. Among impaired individuals (MCI/dementia) (N=40), OEF was positively
associated with VRS (P=0.004, Figure 2c), suggesting that in impaired
patients, OEF can be used to differentiate those attributed to VCI from those
attributed to AD. OEF was not associated with VRS (P=0.49) in normal subjects
(N=25, Figure 2d).
In the whole group, higher OEF was
associated with better composite cognitive score (N=65, P=0.03). Further
analyses showed that there was a positive association between OEF and composite
cognitive score in the low-VRS subgroup (N=44, P=0.002, Figure 3a), but
not in the high-VRS subgroup (N=21, P=0.65, Figure 3b).
In
the subset of subjects (N=43) with CSF measurements, we found a trend of
positive association between OEF and CSF Aβ42/Aβ40 ratio (P=0.06). Further
analyses revealed that, OEF was positively associated with CSF Aβ42/Aβ40 ratio in
the low-VRS subgroup (N=31, P=0.03).
This, together with Figure 3a, strongly support that if the impairment is
primarily attributed to AD, OEF is diminished due to reduced neural function. We
found no association between OEF and Aβ42/Aβ40 ratio in the high-VRS subgroup (N=12,
P=0.71). Similar analyses with total tau and p-tau yielded no
significant effects on OEF (P>0.3).CONCLUSION
This work showed that OEF is differentially
affected by Alzheimer’s (decrease OEF) and vascular (increase OEF) pathology, suggesting
that OEF may be useful in etiology-based diagnosis of cognitive impairment in
elderly individuals. To further enhance the sensitivity and specificity of OEF
to cognitive impairment, development of regional OEF measurement is underway.11,12Acknowledgements
No acknowledgement found.References
- Stevens T,
Livingston G, Kitchen G, Manela M, Walker Z, Katona C. Islington study of
dementia subtypes in the community. Br J Psychiatry 2002;180:270-276.
- Rosenberg GA, Wallin A, Wardlaw JM et
al. Consensus statement for diagnosis of subcortical small vessel disease.
Journal of Cerebral Blood Flow & Metabolism 2016;36:6-25.
- Roman GC, Erkinjuntti T, Wallin A,
Pantoni L, Chui HC. Subcortical ischaemic vascular dementia. Lancet Neurol
2002;1:426-436.
- Buxton RB, Uludag K, Dubowitz DJ, Liu
TT. Modeling the hemodynamic response to brain activation. Neuroimage
2004;23:S220-S233.
- Lu H, Ge Y. Quantitative evaluation
of oxygenation in venous vessels using T2-Relaxation-Under-Spin-Tagging MRI.
Magn Reson Med 2008;60:357-363.
- Jiang D, Deng S, Franklin CG, O'Boyle
M, Zhang W, Heyl BL, Pan L, Jerabek PA, Fox PT, Lu H. Validation of T2 -based
oxygen extraction fraction measurement with (15) O positron emission
tomography. Magn Reson Med 2021;85:290-297.
- Albert MS, DeKosky ST, Dickson D,
Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC. The
diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations
from the National Institute on Aging‐Alzheimer's Association
workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's &
dementia 2011;7:270-279.
- Gottesman RF, Schneider AL, Zhou Y et
al. Association Between Midlife Vascular Risk Factors and Estimated Brain
Amyloid Deposition. JAMA 2017;317:1443-1450.
- Jiang D, Liu P, Li Y, Mao D, Xu C, Lu
H. Cross-vendor harmonization of T2 -relaxation-under-spin-tagging (TRUST) MRI
for the assessment of cerebral venous oxygenation. Magn Reson Med
2018;80:1125-1131.
- Jiang D, Lin Z, Liu P et al. Normal
variations in brain oxygen extraction fraction are partly attributed to
differences in end-tidal CO2. J Cereb Blood Flow Metab 2020;40:1492-1500.
- Jiang D, Lu H, Parkinson C, Su P, Wei
Z, Pan L, Tekes A, Huisman T, Golden WC, Liu P. Vessel-specific quantification
of neonatal cerebral venous oxygenation. Magn Reson Med 2019;82:1129-1139.
- Jiang
D, Koehler R, Liu X, Kulikowicz E, Lee J, Lu H, Liu P. Quantitative validation
of MRI mapping of cerebral venous oxygenation with direct blood sampling: a
graded-O2 study in piglets. Magn Reson Med 2021. (Accepted).